Moffitt Cancer Center: Why we are building the first machine learning department in oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Imagine a future where cancer patients are able to receive the treatment they precisely need and not the treatment that is prescribed to all.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Issam El Naqa, PhD
Chair, Department of Machine Learning, Moffitt Cancer Center
Dana Rollison, PhD
Vice president, chief data officer, associate center director of data science, Division chief, quantitative science, Moffitt Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Issam El Naqa, PhD
Chair, Department of Machine Learning, Moffitt Cancer Center
Dana Rollison, PhD
Vice president, chief data officer, associate center director of data science, Division chief, quantitative science, Moffitt Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login